18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism

Early prognostic stratification is desirable in patients with suspected atypical parkinsonian syndromes (APSs) for optimal treatment and counseling. We investigated the prognostic value of imaging disease-specific metabolism patterns with 18F-FDG PET compared with that of clinical diagnosis. Methods: Seventy-eight patients with suspected APS at study inclusion underwent a follow-up of up to 5.9 y after prospective 18F-FDG PET imaging. Survival data were analyzed by Kaplan–Meier and Cox regression analyses according to diagnostic classifications provided by 18F-FDG PET at baseline and clinical diagnoses after a median follow-up of 1 y after PET. Results: Forty-four of 78 patients were alive 4.7 ± 0.6 y after PET. Patients diagnosed with an APS by PET or 1-y clinical follow-up showed a significantly shorter median survival time (4.1 y, age-adjusted hazard ratios [HRs] = 3.8 for both classifiers) than those diagnosed with Lewy-body diseases (LBDs; majority Parkinson disease [PD]; median survival time not reached). Subgroup classifications of progressive supranuclear palsy/corticobasal degeneration (PSP/CBD) or multiple-system atrophy (MSA) by PET and clinical follow-up were associated with significantly shorter survival than PD. Age-adjusted mortality was significantly increased for PSP/CBD (HR = 5.2) and MSA (HR = 5.6) classified by PET, but for PSP/CBD only when diagnosed by clinical follow-up (HR = 4.5). Patients with a PET pattern suggestive of PD with dementia/dementia with Lewy bodies (PDD/DLB) exhibited a trend toward shorter survival than those with PD (P = 0.07), whereas patients classified as PDD/DLB by clinical follow-up did not (P = 0.65). Conclusion: 18F-FDG PET is an early predictor of survival in patients with clinically suspected APS. Detection of cortical or subcortical hypometabolism by 18F-FDG PET is an unfavorable predictor. Risk stratification by 18F-FDG PET appears to be at least as predictive as the 1-y follow-up clinical diagnosis. This finding strongly supports the early inclusion of PET imaging in patient care.

[1]  R. Albin,et al.  Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study , 2011, The Journal of Nuclear Medicine.

[2]  Günther Deuschl,et al.  The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.

[3]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[4]  I. McKeith,et al.  SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.

[5]  R. Buchert,et al.  [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism , 2012, Neurology.

[6]  Chris C. Tang,et al.  A disease-specific metabolic brain network associated with corticobasal degeneration. , 2014, Brain : a journal of neurology.

[7]  Z. Schwab,et al.  Projection technique for evaluating surgery in Parkinson’s disease , 1969 .

[8]  I Litvan,et al.  Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination , 1998, Journal of neurology, neurosurgery, and psychiatry.

[9]  J. Perlmutter,et al.  Predictors of survival in patients with Parkinson disease. , 2012, Archives of neurology.

[10]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[11]  Joon-Kee Yoon,et al.  A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies , 2007, European journal of neurology.

[12]  V. Lowe,et al.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants , 2014, Journal of Neurology.

[13]  A. Lees,et al.  What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy‐parkinsonism (PSP‐P)? , 2010, Movement disorders : official journal of the Movement Disorder Society.

[14]  Chris C. Tang,et al.  Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis , 2010, The Lancet Neurology.

[15]  Jennifer L. Whitwell,et al.  Corticobasal degeneration: a pathologically distinct 4R tauopathy , 2011, Nature Reviews Neurology.

[16]  H. Shill,et al.  Low clinical diagnostic accuracy of early vs advanced Parkinson disease , 2014, Neurology.

[17]  P. Kempster,et al.  Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. , 2007, Brain : a journal of neurology.

[18]  J. Joutsa,et al.  Diagnostic accuracy of parkinsonism syndromes by general neurologists. , 2014, Parkinsonism & related disorders.

[19]  J. Benito-León,et al.  Mortality from Parkinson's disease: A population‐based prospective study (NEDICES) , 2011, Movement disorders : official journal of the Movement Disorder Society.

[20]  T. Robbins,et al.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  W. Oertel,et al.  Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy , 2013, Movement disorders : official journal of the Movement Disorder Society.

[22]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[23]  L. Frings,et al.  Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases. , 2014, Current opinion in neurology.

[24]  A. Lees,et al.  Does corticobasal degeneration exist? A clinicopathological re-evaluation. , 2010, Brain : a journal of neurology.

[25]  A. Hout,et al.  Dementia and survival in Parkinson disease , 2008, Neurology.

[26]  C. Weiller,et al.  Neuronal Correlates of Clinical Asymmetry in Progressive Supranuclear Palsy , 2014, Clinical nuclear medicine.

[27]  P. Kempster,et al.  Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. , 2008, Brain : a journal of neurology.

[28]  M. Mintun,et al.  Automated detection of the intercommissural line for stereotactic localization of functional brain images. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  W. Kamphorst,et al.  Survival in progressive supranuclear palsy and frontotemporal dementia , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  A. Lang,et al.  The many faces of corticobasal degeneration. , 2007, Parkinsonism & related disorders.

[31]  Shalini Jha,et al.  The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[32]  J. Hodges,et al.  Survival in frontotemporal dementia , 2003, Neurology.

[33]  H. Fujishiro,et al.  A follow up study of non-demented patients with primary visual cortical hypometabolism: Prodromal dementia with Lewy bodies , 2013, Journal of the Neurological Sciences.

[34]  J. Parisi,et al.  Multiple system atrophy: Prognostic indicators of survival , 2014, Movement disorders : official journal of the Movement Disorder Society.

[35]  K. Jellinger,et al.  Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia , 2007, Neurodegenerative Diseases.

[36]  G. Logroscino,et al.  Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. , 2013, Parkinsonism & related disorders.